trending Market Intelligence /marketintelligence/en/news-insights/trending/CCa7sLl4SQF4t4gtWgULQg2 content esgSubNav
In This List

Luminex completes acquisition of Merck KGaA's cell analysis unit in $75M deal

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Luminex completes acquisition of Merck KGaA's cell analysis unit in $75M deal

Luminex Corp. has completed the acquisition of Merck KGaA's cell analysis equipment provider MilliporeSigma in a $75 million cash, stock and asset deal.

The acquisition expands the Austin, Texas-based company's footprint in life science research and broadens its existing offering of flow-based detection systems. The portfolio includes flow cytometry products sold under the brand names Amnis, for cell-based analysis, and Guava, which are high-performance systems based on microcapillary technologies.

Luminex expects the acquisition to contribute $40 million to $50 million toward its 2019 revenues.

Cantor Fitzgerald & Co. acted as financial adviser and Smith Gambrell & Russell LLP served as legal counsel to Luminex.